Business Wire

Prophylaxis to COVID-19 by AFO-202 ß-Glucan Food Supplement From Japan

Share

Caucasian, Hispanic and Afro-American population, when Covid-19 infected, are prone to abnormal blood clotting, that may lead to stroke. Pregnant women and people with comorbidities are also at high risk. Higher mortality has been reported in patients, whose fasting plasma glucose is very high at the time of hospital admission with SARS-COV-2. During this unprecedented pandemic, a prophylaxis to Covid-19 in diabetic population, and strategies for Prevention of Covid-19 associated coagulopathy by consumption of Beta glucanfood supplementproduced by Black yeast Aureobasidium Pullulans AFO-202 strain has been published in Journal of Diabetes and Metabolic Disorders (https://doi.org/10.1007/s40200-020-00664-4) and Thrombosis Journal (https://doi.org/10.1186/s12959-020-00239-6) respectively, recommending clinical studies for its validation in Covid-19 patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201025005031/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Salient features of AFO-202 secreted Nichi-Glucan on its potentials of prophylaxis to Covid-19 related complications through Blood glucose, cholesterol and coagulation system balancing. (Graphic: Business Wire)

COVID-19 virus damages blood vessels, causing clot or thrombus formation resulting in stroke and disruption of the body’s blood clotting system, leading to organ damage and death. Metabolic and immune dysregulation leads to higher mortality in diabetes patients. The AFO-202 derived Nichi-Glucan has potentials to alleviate the cytokine storm, minimize coagulation disruption, and prevent complications of Covid-19 by balancing blood glucose & cholesterol, according to the authors, who have earlier published its immune enhancement and modulation capabilities to help tackle Covid-19 (https://doi.org/10.3389/fimmu.2020.01548). Pilot studies in Diabetic and Dyslipidemic individuals from south Asian population also have been reported (https://doi.org/10.1155/2012/895370).

Unique advantages: Research of Prof. Noboru Fujii on poly-thermo tolerant fungi lead to the successful culture of Aureobasidium Pullulans andMr. Takashi Onaka (President, Sophy Inc) accomplished its industrial scale GMP production in Kochi, Japan, which was approved by Japanese health ministry as a food additive and in the market since 1996. Among several ß-Glucans produced by extraction and purification methods from sources like yeast-cell wall, Shiitake mushroom, Oats, Algae etc, Nichi Glucan is unique, being secreted as an exo-polysaccharideby AFO-202, possessing a distinct structure, water solubility, high purity, functionality and molecular weight of 30,000. Safety has been confirmed by genotoxicity, repeated and long-term administration tests. Recently, a new strain, N-163 secreted product, having advantageous characteristics to contribute to human health is undergoing studies. Nichi Glucan is available in Japan (www.nichiglucan.com) and in India (https://www.amazon.in/dp/B08DFDX2HQ), exported worldwide by GN Corporation.

Disclaimer: Nichi-Glucan is a food supplement, free from 25 most common allergens. It’s not a drug or curative/therapeutic agent.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

GN Corporation Co, Ltd
Samuel JK Abraham
info@gncorporation.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

“e4life” is Present at Expomed Eurasia with its Innovative Device Able to Inactivate Flu and Covid Viruses With an Efficacy over 90%19.4.2024 17:13:00 CEST | Press release

Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419226980/en/ e4life: e4ambient and e4you devices (Photo: Business Wire) This is a perfect occasion for e4life to present its device based on the e4shield technology which is able to inactivate flu and Covid viruses present in the air. A technology, patented in Italy, that uses neither chemical agents nor filtering materials, but it is based on the transmission of electromagnetic waves able to inactivate the viral load in aerosol. “This Exhibition represents an extraordinary opportunity to present our innovative technology (e4shield) in a dynamic and rapidly evolving region as Eurasia. In a climate of growing consciousness of the

Qualcomm Schedules Second Quarter Fiscal 2024 Earnings Release and Conference Call19.4.2024 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its second quarter fiscal 2024 on Wednesday, May 1, 2024, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its second quarter fiscal 2024 results which will be broadcast live on May 1, 2024, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/events. An audio replay will be available at https://investor.qualcomm.com/news-events/events and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international callers may dial (201) 612-7415. Callers should use rese

Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer19.4.2024 14:56:00 CEST | Press release

Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) today announced the appointment of Francois Hardy as Chief Technology Officer (CTO). Francois will join Newmont’s Executive Leadership Team and lead the technical work across the business to improve operational performance and drive growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419973025/en/ Newmont Appoints Mining Industry Veteran Francois Hardy as Chief Technology Officer (Photo: Business Wire) Francois will take over from interim CTO, Dean Gehring, who also served in a dual role as Newmont’s Chief Integration Officer. After a period of transition, Dean will be leaving the company in early July. Francois brings more than 30 years of technical and operational experience in mining to the role. He commenced with Newmont in 2002 and has held roles including Group Head Exploration, Managing Director Africa and General Manager Tanami. “Francois is a stron

SLB Announces First-Quarter 2024 Results, Targeting to Return $7 Billion to Shareholders Over 2024–202519.4.2024 12:50:00 CEST | Press release

SLB (NYSE: SLB) today announced results for the first-quarter 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417469361/en/ The exterior of the SLB headquarters in Houston, Texas (Photo: Business Wire) First-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeMar. 31, 2024Dec. 31, 2023Mar. 31, 2023 SequentialYear-on-yearRevenue $8,707 $8,990 $7,736 -3% 13% Income before taxes - GAAP basis $1,357 $1,433 $1,161 -5% 17% Income before taxes margin - GAAP basis 15.6% 15.9% 15.0% -35 bps 58 bps Net income attributable to SLB - GAAP basis $1,068 $1,113 $934 -4% 14% Diluted EPS - GAAP basis $0.74 $0.77 $0.65 -4% 14% Adjusted EBITDA* $2,057 $2,277 $1,788 -10% 15% Adjusted EBITDA margin* 23.6% 25.3% 23.1% -171 bps 51 bps Pretax segment operating income* $1,649 $1,868 $1,391 -12% 19% Pretax segment operating margin* 18.9% 20.8% 18.0% -184 bps 95 bps Net income attributable to SLB, excluding cha

Zayo Group Appoints New CEO of Zayo Europe19.4.2024 09:00:00 CEST | Press release

Zayo Group, a leading global provider of network infrastructure, has appointed Colman Deegan as its new CEO of Zayo Europe to drive the business’ growth as cloud and AI adoption continues across the continent. This appointment is effective as of April 16, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419471253/en/ Colman Deegan, CEO Zayo Europe (Photo: Business Wire) Steve Smith, CEO Zayo Group, says, “Colman’s experience and proven track record as a CEO leading large teams and businesses makes him perfectly equipped to take our European business to new heights, together with our outstanding local team. Colman will drive Zayo forward, strengthening our partnerships with data centres, hyperscalers, and enterprises across Europe. Under Colman’s leadership, we are confident that we will achieve our bold ambitions and maximise our impact in the European market.” Deegan spent more than two decades at Vodafone where he h

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye